Prostate Cancer Prevention Trial With Quercetin and Genistein

Launched by UNIVERSITY OF HOHENHEIM · Feb 20, 2012

Keywords

ClinConnect Summary

Prostate cancer (PC) is the most frequently occurring cancer in men. Its clinical incidence and mortality rates vary geographically, being much lower in Asia than in Western countries. Notably, latent PCs seem to be equally distributed, thus supporting the hypothesis, that environmental factors may be important in prostate cancer progression. Moreover, epidemiological evidence strongly supports the concept that the incidence of clinical prostate cancer depends on lifestyle factors, mainly related to diet. The isoflavone genistein and the flavonoid quercetin have been identified as likely pr...

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• * Patients with deviant PSA constellation:
• • 1. Patients with PSA 2,5 - 4 μg/l and free PSA/total PSA \< 15 %
• • 2. Patients with PSA \> 4 μg/l with negative punch biopsy of the prostate
• Exclusion Criteria:
• • chronic liver diseases, impaired kidney function
• • inflammatory diseases of the urogenital tract
• • history of malignancy of any organ system, treated or untreated, within the past three years whether or not there is evidence of local recurrence or metastases
• • therapy with Doxazosin, Dutaserid and/ or Finasterid, Testosteron and other hormonal active medicaments
• • inflammatory bowel diseases
• • malabsorption/-digestion
• • hypersensitivity/allergy to soy
• • phytotherapy or intake of dietary supplements
• • smoker
• • abnormal clinical laboratory values at baseline
• • participation in any other trial with an investigational new drug
• • inability to sign informed consent